Table 3.

Efficacy Outcomes with Peginterferon (PEG) and Ribavirin (RBV) with or without Boceprevir (BOC) in the SPRINT-2 Trial

Outcome	Nonblack patients			Black patients
	BOC (RGT) + PEG/RBV (n=316)	BOC (44 weeks) + PEG/RBV (n=311)	PEG/RBV (n=311)	BOC (RGT) + PEG/RBV (n=52)	BOC (44 weeks) + PEG/RBV (n=55)	PEG/RBV (n=52)
SVR, %
Overall	67	68	40	42	53	23
Patients with Week 4 HCV RNA decline <1 log10 IU/mL, %	29	39	5	25	31	0
Patients with Week 4 HCV RNA decline ≥1 log10 IU/mL, %	82	82	52	67	61	46
Relapse, %	9	5	23	12	17	14

HCV

hepatitis C virus

RGT

response-guided therapy

SVR

sustained virologic response.